Nuo Therapeutics Reports $1.03 Million Revenue for Q3 2025, Net Loss of $537,919

Nuo Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenues of approximately $1.03 million for the third quarter, a substantial increase from $371,000 in the same period last year. This growth was primarily driven by product sales of $957,096 and $75,000 in distribution fee revenue from a new agreement with Smith+Nephew. For the nine months ending September 30, 2025, total revenues reached approximately $2.22 million, compared to $970,301 for the same period in 2024. Gross profit for the quarter was approximately $625,375, up from $270,447 in the prior year, although the gross margin decreased to 61% from 73% due to lower margins on products sold to Smith+Nephew.

The company’s operating expenses also increased, totaling approximately $1.17 million for the third quarter, compared to $848,000 in the previous year. This rise was attributed to higher professional fees, increased commission expenses for sales representatives, and additional compensation costs related to new personnel. Despite the increase in revenues, Nuo Therapeutics reported a net loss of $537,919 for the quarter, slightly improved from a loss of $578,167 in the same quarter of 2024. For the nine-month period, the net loss was approximately $1.93 million, compared to $1.83 million in the prior year.

Nuo Therapeutics has made strategic advancements, particularly through its distribution agreement with Smith+Nephew, which commenced on March 31, 2025. This agreement allows Smith+Nephew to distribute a private label version of Nuo's Aurix product, with an upfront fee of $1.5 million recognized as deferred revenue to be amortized over five years. The company has also expanded its sales network, establishing relationships with over 200 third-party representatives, which is expected to enhance its market presence in the chronic wound care sector.

Operationally, Nuo Therapeutics has seen an increase in customer engagement, with product revenues attributed to a growing customer base and initial sales under the Smith+Nephew agreement. The company reported cash balances of approximately $514,797 as of September 30, 2025, an increase from $283,714 at the end of 2024. However, the company continues to face challenges, including an accumulated deficit of approximately $34.2 million and ongoing concerns regarding its ability to sustain operations without additional capital. The management has indicated that while they are optimistic about future revenue growth, substantial doubt remains about the company's ability to continue as a going concern without securing further funding.